CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key points:
- CEO John Climaco will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be accessible on the Company's website and archived for 90 days
This presentation offers an opportunity for CNS Pharmaceuticals to showcase its developments and engage with the investment community.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CNSP declined 1.19%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for CNS Pharmaceuticals (CNSP) at the investment conference?
Where can investors view the webcast of CNS Pharmaceuticals' (CNSP) presentation?
How long will the webcast of CNS Pharmaceuticals' (CNSP) presentation be available?
What is the focus of CNS Pharmaceuticals' (CNSP) research and development?
